Pharmaceuticals

Asia's largest pharma show returns, showcasing China's evolution from the world's factory to a global hub of drug innovation and supply chain strategy.

With a strong cash position and promising drug candidate, Apogee Therapeutics is advancing multiple trials to challenge the I&I market with a new therapy.

Lynk Pharmaceuticals reports its oral drug zemprocitinib met all goals in a late-stage study for atopic dermatitis, offering rapid itch relief and a strong safety profile.

As MSA Awareness Month begins, a novel drug from Alterity Therapeutics shows significant promise in slowing the devastating and untreatable neurodegenerative disease.

A key clinical milestone for its MS drug azer-cel nets Precision BioSciences $7.5M, extending its financial runway and boosting hope for patients.

With a strong cash runway and pivotal trials underway, Sionna Therapeutics aims to revolutionize CF treatment with a novel class of NBD1 stabilizer drugs.

Zymeworks lands $250M from Royalty Pharma in a non-dilutive deal, validating its cancer drug Ziihera and highlighting a new era of biotech financing.

With positive Phase 3 data for its first-in-class Stargardt disease drug and a massive new financing round, Belite Bio pivots toward commercialization.

At the India AI Impact Summit, experts warned that AI crises will move at machine speed. Can global diplomacy and safety protocols catch up before it's too late?

Shareholder approval paves the way for cancer therapy innovator VERAXA to go public, aiming to accelerate its next-gen antibody-drug conjugate pipeline.

The FDA has greenlit Ascendis Pharma's once-weekly YUVIWEL for achondroplasia, a major step for patients that also carries significant business implications.

Facing delisting for being a 'public shell,' XTL Biopharma plans an appeal while its new acquisition and valuable IP hang in the balance.

As Cipla rolls out its affordable Liraglutide injection, the battle for the multi-billion dollar GLP-1 market intensifies, promising greater access for patients.

The stars join The Elizabeth Taylor AIDS Foundation to modernize laws from the '80s that criminalize HIV status, clashing with modern science.

As Canada prepares for generic Semaglutide, U.S. patients look north for relief from soaring drug costs, navigating a complex web of savings and risks.

On Rare Disease Day, Polaryx Therapeutics advances a novel oral drug in a pivotal trial for four devastating pediatric disorders, offering a new strategy.

A new emergency epilepsy medication for children is now available, offering a faster, easier-to-use option for caregivers to stop prolonged seizures.

A key European panel recommends Dupixent for children with chronic hives, offering a potential first-of-its-kind targeted therapy for a difficult condition.

A new oral therapy, mavorixafor, receives a key recommendation in Europe, offering a beacon of hope for patients with a debilitating ultra-rare immune disorder.

The Mexican pharma giant saw sales fall in 2025 but improved margins, strategically clearing inventory and reinvesting savings for a planned 2026 recovery.